Monday, June 1, 2026

Artiva to Advance NK Cell Therapy Into Phase 3 for Rheumatoid Arthritis After Positive Mid-Stage Data

GC Cell's Artiva Biotherapeutics advances NK cell therapy AlloNK to Phase 3 trials for rheumatoid arthritis after promising Phase 2 results.

Tag: political repercussions

No posts to display

Top News

- Our Sponsors Ad -

Follow us